Active ingredientChlorprothixene HydrochlorideCat. No. P-C145-001CAS 6469-93-8Family · Pharmaceutical analytical standards
Chlorprothixene
The first antipsychotic of the thioxanthene family to be synthesised, introduced in 1959: it is used for schizophrenia and manic episodes, and has a marked sedative effect. This family brings together the active ingredient, pharmacopoeial impurities and nitrosamines.
Did you know?Besides psychosis, it is also used for anxiety and insomnia before and after surgery and for severe nausea and vomiting in hospitalised patients.
Go to the active ingredient →Active ingredientChlorprothixene HydrochlorideCat. No. P-C145-001CAS 6469-93-8
Pharmacopoeial impurityChlorprothixene EP Impurity ACat. No. P-C145-002CAS 4295-65-2
Pharmacopoeial impurityChlorprothixene EP Impurity B HClCat. No. P-C145-003CAS 4907-84-0
Pharmacopoeial impurityChlorprothixene EP Impurity CCat. No. P-C145-004CAS 51382-91-3
Pharmacopoeial impurityChlorprothixene EP Impurity D HClCat. No. P-C145-005
Pharmacopoeial impurityChlorprothixene EP Impurity ECat. No. P-C145-006CAS 86-39-5
NitrosamineN-Nitroso Chlorprothixene EP Impurity CCat. No. P-C145-007
Pharmacopoeial impurityChlorprothixene EP Impurity F HClCat. No. P-C145-009CAS 2461-06-5
Active ingredientChlorprothixeneCat. No. P-C145-010CAS 113-59-7No product matches your search.
EDQM standards 1
The official European Pharmacopoeia standards for this family.
Reference substanceChlorprothixene hydrochloride CRSEDQM code C1915000Family ChlorprothixeneNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.